CancerNetwork® sat down with Ola Landgren, MD, PhD, at the 2021 EHA Congress to talk about his presentation on first-line standard of care for multiple myeloma.
Ola Landgren, MD, PhD
Multiple Myeloma Cancer Chair
Chief, Myeloma Program
Leader, Experimental Therapeutics Program
Sylvester Comprehensive Cancer Center
Professor of Medicine
University of Miami
Miami, FL
Hematologic oncologist, Ola Landgren, MD, PhD, was recently appointed the inaugural leader of a new research program, Experimental Therapeutics, at Sylvester Comprehensive Cancer Center at the University of Miami Health System and the Miller School of Medicine. Landgren completed his medical degree and doctorate at Karolinska Institute in Stockholm, Sweden. He is board certified in hematology and internal medicine. As part of his ongoing research program, Landgren is studying molecular mechanisms underlying the trajectory from precursor to full-blown multiple myeloma with the goal to develop treatment strategies aiming to delay, prevent, and ultimately define a cure for multiple myeloma.
Advertisement
Ola Landgren, MD, PhD, looks at results from the phase 2 CARTITUDE-2 trial of ciltacabtagene autoleucel for patients with multiple myeloma and 1 to 3 prior lines of therapy presented at the 2021 ASCO Annual Meeting.
In this issue of ONCOLOGY, Dr. Robert Kyle and colleagues provide their clinical and epidemiological perspective on monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM)-a perspective that is based on more than three decades of experience.
Advertisement
Advertisement
